← All indications
Sphingolipidoses
A group of inherited metabolic disorders characterized by the intralysosomal accumulation of SPHINGOLIPIDS primarily in the CENTRAL NERVOUS SYSTEM and to a variable degree in the visceral organs. They are classified by the enzyme defect in the degradation pathway and the substrate accumulation (or storage). Clinical features vary in subtypes but neurodegeneration is a common sign.
Subtype terms (8)
More specific conditions that are subtypes of Sphingolipidoses in the MeSH hierarchy.
- Fabry Disease
30 drugs (16 approved, 14 experimental)
- Farber Lipogranulomatosis
- Gangliosidoses
1 drug experimental
- Gaucher Disease
37 drugs (20 approved, 17 experimental)
- Leukodystrophy, Globoid Cell
19 drugs (12 approved, 7 experimental)
- Niemann-Pick Diseases
10 drugs (7 approved, 3 experimental)
- Sea-Blue Histiocyte Syndrome
- Sulfatidosis
Drugs by status
Organizations
Organization Involved with Phase 2 Indications (1)